Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer's Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study

BACKGROUND/AIMS: A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer's disease (AD) detected a treatment benefit to cognition in apolipoprotein E (APOE)-∊4-negative subjects. The current phase III stu...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Gold, Michael, Alderton, Claire, Zvartau-Hind, Marina, Egginton, Sally, Saunders, Ann M., Irizarry, Michael, Craft, Suzanne, Landreth, Gary, Linnamägi, Ülla, Sawchak, Sharon
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: S. Karger AG 2010
Aiheet:
Original Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3214882/
https://ncbi.nlm.nih.gov/pubmed/20733306
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000318845
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia